<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30173230</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Print">0126-8635</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>40</Volume>                    <Issue>2</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                    </PubDate>                </JournalIssue>                <Title>The Malaysian journal of pathology</Title>                <ISOAbbreviation>Malays J Pathol</ISOAbbreviation>            </Journal>            <ArticleTitle>Stromal podoplanin expression and its clinicopathological role in breast carcinoma.</ArticleTitle>            <Pagination>                <MedlinePgn>137-142</MedlinePgn>            </Pagination>            <Abstract>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Breast cancer is still a serious health problem in 21st century and diagnosis, treatment and prognosis of this malignant disease are subject to many research. While cancer research has been focused on tumour cells primarily, recent studies showed that tumour stroma contribute to carcinogenesis as well as tumour cells. Especially fibroblasts adjacent to epithelial tumour cells are not ordinary fibroblasts and play the critical role. Studies showed that these cancer associated fibroblasts (CAFs) have different genetic profile and protein expression. One of the differently expressed molecules recently found is podoplanin. Podoplanin, utilised as a lymphatic endothelial marker, is found to be expressed in CAFs. The aim of this study is to evaluate the relationship between the stromal expression of podoplanin in invasive breast carcinoma and clinicopathological parameters.</AbstractText>                <AbstractText Label="MATERIALS &amp; METHODS" NlmCategory="METHODS">Podoplanin expression was evaluated immunohistochemically in 153 breast cancers. Tumours with â‰¥ 10% distinct cytoplasmic podoplanin staining in CAFs were considered as positive.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In 65.3% of analysed tumours, podoplanin expression was found positive in CAFs. According to our results, podoplanin positive CAFs correlated significantly with tumour size (p= 0.012), tumour grade (p= 0.032) and cerbB2 score (p= 0.032).</AbstractText>                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Our results suggest that podoplanin expression by CAFs could predict poor patient outcome in breast carcinoma.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kumcu</LastName>                    <ForeName>E</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Bingol State Hospital, Bingol, Turkey. emrahkumcu85@hotmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Unverdi</LastName>                    <ForeName>H</ForeName>                    <Initials>H</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Kaymaz</LastName>                    <ForeName>E</ForeName>                    <Initials>E</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Oral</LastName>                    <ForeName>O</ForeName>                    <Initials>O</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Turkbey</LastName>                    <ForeName>D</ForeName>                    <Initials>D</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Hucmenoglu</LastName>                    <ForeName>S</ForeName>                    <Initials>S</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Malaysia</Country>            <MedlineTA>Malays J Pathol</MedlineTA>            <NlmUniqueID>8101177</NlmUniqueID>            <ISSNLinking>0126-8635</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30173230</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>